Evidence map›Paper›PMID 30552384›Full record

ArticleOncogene2019

Upregulation of MLK4 promotes migratory and invasive potential of breast cancer cells.

Anna A Marusiak, Monika K Prelowska, Dawid Mehlich, Michal Lazniewski, Klaudia Kaminska, Adam Gorczynski, Aleksandra Korwat, Olga Sokolowska, Hanna Kedzierska, Jakub Golab and 4 more

Abstract read
In one paragraph

Article in Oncogene, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Genomic control of metastasis.British journal of cancer · 2021
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Anna A MarusiakLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland. a.marusiak@cent.uw.edu.pl.
Monika K PrelowskaLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Dawid MehlichLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Michal LazniewskiLaboratory of Functional and Structural Genomics, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Klaudia KaminskaLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Adam GorczynskiDepartment of Pathomorphology, Medical University of Gdansk, Gdańsk, Poland.
Aleksandra KorwatDepartment of Pathomorphology, Medical University of Gdansk, Gdańsk, Poland.
Olga SokolowskaLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Hanna KedzierskaLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.
Jakub GolabDepartment of Immunology, Medical University o``f Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0002-2830-5100
Wojciech BiernatDepartment of Pathomorphology, Medical University of Gdansk, Gdańsk, Poland.
Dariusz PlewczynskiLaboratory of Functional and Structural Genomics, Centre of New Technologies, University of Warsaw, Warsaw, Poland.ORCID http://orcid.org/0000-0002-3840-7610
John BrognardNational Cancer Institute, Frederick, MD, USA.
Dominika NowisLaboratory of Experimental Medicine, Centre of New Technologies, University of Warsaw, Warsaw, Poland.

Funding

Oncogenic Kinases in CancerZIABC011691 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI BROGNARD, JOHN · 2016 to 2025
$14.4M
6 · The paper itself

Abstract

Metastasis to distant organs is a major cause for solid cancer mortality, and the acquisition of migratory and invasive phenotype is a key factor in initiation of malignancy. In this study we investigated the contribution of Mixed-Lineage Kinase 4 (MLK4) to aggressive phenotype of breast cancer cells. Our TCGA cancer genomic data analysis revealed that amplification or mRNA upregulation of MLK4 occurred in 23% of invasive breast carcinoma cases. To find the association between MLK4 expression and the specific subtype of breast cancer, we performed a transcriptomic analysis of multiple datasets, which showed that MLK4 is highly expressed in triple-negative breast cancer compared to other molecular subtypes. Depletion of MLK4 in cell lines with high MLK4 expression impaired proliferation and anchorage-dependent colony formation. Moreover, silencing of MLK4 expression significantly reduced the migratory potential and invasiveness of breast cancer cells as well as the number of spheroids formed in 3D cultures. These in vitro findings translate into slower rate of tumor growth in mice upon MLK4 knock-down. Furthermore, we established that MLK4 activates NF-κB signaling and promotes a mesenchymal phenotype in breast cancer cells. Immunohistochemical staining of samples obtained from breast cancer patients revealed a strong positive correlation between high expression of MLK4 and metastatic potential of tumors, which was predominantly observed in TNBC subgroup. Taken together, our results show that high expression of MLK4 promotes migratory and invasive phenotype of breast cancer and may represent a novel target for anticancer treatment.

Indexed as

AnimalsCell LineCell Line, TumorCell MovementCell ProliferationFemaleHEK293 CellsHumansMAP Kinase Kinase KinasesMCF-7 CellsMiceNeoplasm InvasivenessNF-kappa BSignal TransductionTranscriptomeTriple Negative Breast NeoplasmsMAP3K21 protein, humanMAP Kinase Kinase KinasesNF-kappa B

Identifiers

PMID30552384
PMCPMC6484767

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.